NAD+ side effects belong to four different things at once
Separating them is the useful thing this page can do, because a clinic answering the question will generally answer for the first source only, and answer it accurately.
The first source is the molecule, which is the only one anyone means by the question.
The second is the rate at which it is delivered, and in practice this is where most reported discomfort sits.
The third is the route, meaning a needle, a line and a solution entering a vein, with the risks that belong to any infusion regardless of contents.
The fourth is the absence of a licensed product, which does not cause harm directly but removes every system built to detect, record and warn about harm.
A provider asked whether it is safe will normally be describing what they have seen in their own clients, which covers sources one and two, over the period they were watching. That is a real answer to a narrower question than the one asked.
What people report while the line is running
The consistent thread in what clinicians describe is that discomfort tracks speed rather than total volume.
Reported experiences during infusions include nausea, flushing, a feeling of chest tightness or pressure, abdominal cramping, headache and light headedness. Providers manage these by slowing the drip, which is why sessions in this market run long. Some clinics say so openly, which is to their credit, and it tells you plainly that the intervention has a sharp edge that has to be managed.
These accounts come from humans, in clinics, receiving the infused coenzyme. That is worth stating because it is one of the few places in this subject where the human, infused evidence is the evidence, even if it is uncontrolled observation rather than trial data. It describes tolerability rather than effect.
What it cannot describe is anything appearing later. Nobody is following these clients for months with a structured questionnaire, so an effect emerging at six weeks would leave no trace.
Infection, air and infiltration: the cannula's own list
An hour with a line in your arm carries its own hazards, and they are independent of what is flowing through it.
The list is unglamorous and well understood in nursing practice: infection at the insertion site or in the bloodstream, a vein becoming inflamed, fluid leaking into surrounding tissue, bruising, and rarely an air embolism. In a hospital these are managed by protocol, audited, and reported. In a private clinic they depend on the standards of that particular practice, and in a mobile service delivered in someone's home they depend on standards nobody is inspecting.
This is the part of the risk that a good clinic genuinely reduces. A trained person, sterile technique, proper equipment and someone present who can stop are worth paying for, and a page pretending otherwise would be wrong. It is also the part that a vial bought online and used at home does not reduce at all.
Where an oral precursor's safety record stops applying
Reassurance in this market is frequently borrowed. Oral nicotinamide riboside and nicotinamide mononucleotide have been given to humans in trials, and those trials have not reported a pattern of serious problems.
That record belongs to a different molecule, taken by a different route, at amounts absorbed and converted over hours. It does not transfer to a solution of the finished coenzyme delivered into a vein, and the transfer is exactly what a page does when it answers a question about infusions by citing precursor safety data without naming which was given.
The same applies to the oldest reassurance of all, that the body makes this substance itself. It does, in particular compartments, at particular rates, under regulation. An infusion is not a larger version of that process.
Risk, source by source
The final column is the one that should hold your attention. Four of five rows end in nothing being recorded anywhere that another person could ever read.
| Where the harm comes from | What has actually been observed, and in what | Who would notice it | Where it gets recorded |
|---|---|---|---|
| The molecule itself, infused | Very little in humans beyond clinic observation | Nobody systematically | Nowhere |
| Delivery rate | Nausea, flushing, chest tightness, cramping, reported in humans during sessions | You, immediately | The clinic's own notes, if kept |
| The line and the solution | Standard infusion risks, well documented in humans in clinical settings | Clinic staff, then you | Practice records only |
| An unverified vial used at home | Unknown contents, unknown sterility | Nobody, until something goes wrong | Nowhere |
| Long term or rare effects | Not studied in humans for the injected form | Nobody | Nowhere |
The cancer question, and how to hold it honestly
There is a theoretical concern in this area that marketing does not raise and that alarmist writing overstates. It deserves to be put carefully.
The coenzyme is essential to cell metabolism, and dividing cells, including malignant ones, depend on it. Work in cultured cells and in mice has examined the salvage pathway as a target in cancer biology, with interest running in both directions: some research explores blocking the pathway to starve tumours, other research examines whether raising availability could support cell survival in ways that are not always desirable.
What this does not amount to is evidence that infusions cause or accelerate cancer in people. No such finding exists, and claiming it would be as unfounded as the claims on the other side.
What it does amount to is a reason that a substance with this much biological reach should not be assumed harmless simply because the body makes it. The mechanism is not inert, which is the whole basis of the sales pitch, and a mechanism that is not inert has more than one direction available to it. Anyone with a current or previous cancer diagnosis has a specific reason to discuss this with their own oncology team rather than with a drip clinic.
The absence of a place to report anything
Suppose something does happen to you three weeks after a course. Follow where that information goes.
A licensed medicine has a route: a national reporting scheme, a manufacturer obliged to investigate, a regulator watching for patterns across a population, and a mechanism for changing the leaflet or withdrawing the product. Rare harms are found this way and almost no other way, because they are too infrequent for any trial to catch.
An unapproved infusion has none of that. Your report goes to the clinic that sold it, if you tell them at all. It is not aggregated with anyone else's. No pattern can form, because there is no surface for a pattern to form on. The reassuring absence of reported problems in this market is therefore not a clean safety record. It is the shape of a record that was never being kept.